- Home
- TRC vs VOR Comparison
TRC vs VOR Comparison
Compare TRC & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TRC | VOR |
|---|---|---|
| Founded | 1843 | 2015 |
| Country | United States | United States |
| Employees | 88 | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 476.6M | 562.6M |
| IPO Year | 1995 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TRC | VOR |
|---|---|---|
| Price | $18.09 | $15.19 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $64.78 |
| AVG Volume (30 Days) | 75.8K | ★ 696.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 2.86 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $37,830,000.00 | N/A |
| Revenue This Year | $2.31 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.04 | $0.13 |
| 52 Week High | $19.39 | $49.95 |
Technical Indicators
Market Signals| Indicator | TRC | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 71.94 | 55.44 |
| Support Level | $18.06 | $11.76 |
| Resistance Level | $19.20 | $16.95 |
| Average True Range (ATR) | 0.47 | 1.13 |
| MACD | 0.07 | 0.16 |
| Stochastic Oscillator | 96.27 | 57.80 |
Price Performance
Historical ComparisonAbout TRC Tejon Ranch Co
Tejon Ranch Co is a diversified real estate development and agribusiness company committed to responsibly using its land and resources to meet the housing, employment, and lifestyle needs of Californians and create value for its shareholders. It has five segments namely Real Estate - Commercial/Industrial, Real Estate - Resort/Residential, Mineral Resources, Farming, and Ranch Operations.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.